middle molecular clearance in citrate-based dialysis using a conventional vs. high-cutoff dialyzer

middle molecular clearance in citrate-based dialysis using a conventional vs. high-cutoff dialyzer - CIMIC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00005254

Enrollment

Registered

2013-11-26

Start date

2013-12-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N17

Interventions

Group 1: CVVHD with regional citrate anticoagulation: therapy period: max. 72h, 5 blood samples ahead and after dialyzer Group 2: CVVHD with regional citrate anticoagulation using large-pored EMiC®2-

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: acute dialysis dependent renal failure

Exclusion criteria

Exclusion criteria: therapeutic anticoagulation necessary in other indication; younger than 18 years; high risk of citrate accumulation (for instance acute liver failure); refusal of or contraindications for renal replacement therapie; predicted survival less than 48 h; pregnancy or lactation; member in other clinical trials; decline participation in study

Design outcomes

Primary

Measure	Time frame
ß2-Mikroglobulin Clearance after 1 h, 6 h, 12 h, 24 h und 48 h (estimated by serum levels before and after dialyzer)	—

Secondary

Measure	Time frame
Clearance of Urea, Creatinin, Myoglobin and IL-6 after 1 h, 6 h, 12 h, 24 h und 48 h (estimated by serum levels before and after dialyzer)	—

Countries

Germany

Contacts

Public ContactLorenz Weidhase

Universitätsklinikum Leipzig, DIND, Interdisziplinäre Internistische Intensivmedizin

lorenz.weidhase@medizin.uni-leipzig.de+493419712705

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 21, 2026